AJ Lanigan: Indeed. In Reality, pharma companies are earning big revenue with therapies like Keytruda and Opdivo that deal with PD-one and PD-L1. In this article’s the super interesting portion: think of checkpoints as traffic signals. You don’t want an immune system that’s running wild just like a freight prepare waiting for link from Social Bookmarking (3)